COMMUNIQUÉS West-GlobeNewswire

Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
02/02/2024
PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of [...]
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
02/02/2024
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host [...]
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
02/02/2024
- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality was reported over the [...]
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
02/02/2024
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* -- -- Current Nitisinone market is estimated to exceed $50 million annually -- -- Product is now available exclusively [...]
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
02/02/2024
Media Release COPENHAGEN, Denmark; February 2, 2024 Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (Nasdaq: GMAB ) and Pfizer, Inc. (NYSE PFE) today a nnounced that the European Medicines [...]
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
02/02/2024
Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding Ronapreve TM (a)(b) , revenues increased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022 [...]
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
02/02/2024
TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application [...]
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
02/02/2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals (“Inmagene”) [...]
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed
02/02/2024
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024 Company announcement No. 07 On January 29, 2024, following the satisfaction of all conditions precedent, the [...]
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
02/02/2024
SHANGHAI, China, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units
02/02/2024
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 01, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX [...]
Fractyl Health Announces Pricing of Initial Public Offering
02/02/2024
LEXINGTON, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today [...]
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
01/02/2024
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47 th Annual Meeting of the Macula Society, with company-sponsored webcast on [...]
NADP Research Reveals Record in Dental Coverage for Americans
01/02/2024
Nearly 300 million, 88% of Population, Enrolled in Dental Benefits in 2022 DALLAS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- At year-end 2022, a record 293 million Americans had dental coverage according to the 2023 Benefits [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/02/2024
NEW YORK and SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule [...]
Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C.
01/02/2024
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 01, 2024 ( [...]
ARCA biopharma Announces 2023 Financial Results
01/02/2024
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA [...]
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
01/02/2024
Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“ [...]
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
01/02/2024
NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck [...]

Pages